Ofatumumab

證據等級: L5

預測適應症: 8 個

Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma

One-Sentence Summary

Ofatumumab (DrugBank DB06650) is a fully human anti-CD20 monoclonal antibody whose established use is in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) — confirmed within this evidence pack by the head-to-head RESONATE and DUO trials (rank 5 candidate). Among the TxGNN model’s outputs, the strongest evidence-backed new-indication signal is Follicular Lymphoma, supported by 15 clinical trials (including 2 randomized Phase 2/3 studies) and 20 publications. Note: the model’s raw top-ranked outputs (rank 1–2, IGHV-mutation subtype nodes; rank 4, a genetic-susceptibility node; ranks 7–8, CD20-negative tumors) carry no clinical or literature evidence and are flagged in the evidence pack itself as ontology artifacts — Follicular Lymphoma is the highest-evidence genuinely novel signal.

Quick Overview

Item	Content
Original Indication	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) — per the RESONATE (NCT01578707) and DUO (NCT02004522) trial evidence in this pack, ofatumumab is used as monotherapy comparator/standard for relapsed-refractory CLL/SLL; no formal license record exists in this dataset
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.70%
Evidence Level	L2
US Market Status	Not marketed (per this dataset; 0 license records)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, a structured mechanism-of-action (MOA) field is not available for this drug (flagged as data gap DG002, High severity). However, literature captured within this evidence pack (e.g. PMID 20068404, PMID 18535937, PMID 22830942) consistently describes ofatumumab as a fully human IgG1κ monoclonal antibody that binds a membrane-proximal epitope on CD20, triggering B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

Follicular lymphoma is, like CLL/SLL, a CD20-positive B-cell malignancy. The mechanistic rationale is therefore direct: the same CD20-targeting activity that clears malignant B cells in CLL/SLL applies to FL’s malignant B-cell clone. This is reinforced by clinical precedent — rituximab, ofatumumab’s same-class predecessor, is already a backbone therapy in FL — and by the trial evidence below, which shows ofatumumab tested across frontline, maintenance, and relapsed/refractory FL settings.

By contrast, several other TxGNN outputs in this pack (IGHV-mutation subtype, pregerminal-center subtype, genetic-susceptibility node, malignant spiradenoma, Langerhans cell histiocytosis) are explicitly annotated in their own repurposing_rationale fields as ontology-driven artifacts lacking any CD20-relevant biological basis or supporting evidence — these were excluded from the headline signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01190449	Phase 2	Completed	51	Single-agent ofatumumab in previously untreated Stage II–IV follicular NHL
NCT01294579	Phase 2	Completed	49	Ofatumumab + bendamustine induction, followed by ofatumumab maintenance, in indolent B-NHL relapsed after rituximab
NCT01077518	Phase 3	Terminated	346	Ofatumumab + bendamustine vs. bendamustine alone in rituximab-unresponsive indolent B-NHL; terminated before full readout
NCT02710643	Phase 2	Completed	110	Involved-field radiotherapy ± ofatumumab in Stage I/II FL, stratified by Bcl-2 status (MIRO trial)
NCT00494780	Phase 2	Completed	59	Two-dose ofatumumab + CHOP as frontline therapy for untreated FL
NCT00394836	Phase 2	Completed	116	Ofatumumab monotherapy in rituximab-refractory FL
NCT01286272	Phase 2	Completed	135	Ofatumumab + bendamustine ± bortezomib in untreated FL
NCT00742144	Phase 1	Completed	6	Safety/PK of ofatumumab monotherapy in Japanese FL/CLL patients
NCT01239394	Phase 2	Completed	43	Ofatumumab as initial systemic treatment for indolent B-cell lymphoma
NCT00823719	Phase 2	Completed	61	Ofatumumab + ICE/DHAP salvage chemotherapy pre-autologous transplant in relapsed/refractory aggressive lymphoma

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31174236	2019	RCT (Phase 2)	Cancer	CALGB 50904: ofatumumab+bendamustine vs. ofatumumab+bendamustine+bortezomib in untreated high-risk FL
30723894	2019	RCT (Phase 2)	Br J Haematol	CALGB 50901: single-agent ofatumumab efficacy in untreated low/intermediate-risk FL
38937025	2024	Phase 2 trial	Lancet Haematology	FIL MIRO final results: MRD-driven radiotherapy ± ofatumumab in early-stage FL
22389254	2012	Cohort (multicenter)	Blood	Ofatumumab monotherapy in rituximab-refractory FL; ORR 13%, modest activity in heavily pretreated disease
22409295	2012	Phase 2 cohort	Br J Haematol	O-CHOP (ofatumumab + CHOP) as frontline therapy for FL
18390837	2008	Phase 1/2	Blood	First clinical use of ofatumumab in relapsed/refractory FL
28983798	2017	Review	Advances in Therapy	20-year review of rituximab (anti-CD20 class) across B-cell malignancies including FL
21083037	2010	Review	Expert Rev Hematol	Emerging therapeutic strategies in follicular lymphoma
26043777	2015	Review	Expert Opin Biol Ther	Ofatumumab activity across CD20+ B-cell lymphomas
29934061	2018	Review	Clin Lymphoma Myeloma Leuk	Evidence-based review of anti-CD20 regimens in relapsed/refractory CLL, DLBCL, and FL

US Market Information

No marketing authorization records are present in this dataset (total_licenses = 0, market_status = 未上市/Not marketed). This does not necessarily reflect ofatumumab’s actual global regulatory history — it reflects a gap in the source registry used to build this evidence pack.

Cytotoxicity

Ofatumumab is an antineoplastic biologic (anti-CD20 monoclonal antibody used in B-cell malignancies), so this section applies — but it is not a conventional cytotoxic chemotherapy agent.

Item	Content
Cytotoxicity Classification	Immunotherapy — CD20-targeted monoclonal antibody (not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Not directly reported in this dataset. As a monoclonal antibody, direct myelosuppression is expected to be lower than cytotoxic chemotherapy; however, the combination regimens documented above (e.g., ofatumumab+bendamustine, O-CHOP) carry the conventional myelosuppression risk of their chemotherapy partners
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential; infusion-related reaction monitoring; hepatitis B reactivation screening (standard precaution for anti-CD20 antibody class)
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are marked as data gaps in this evidence pack — DG001, Blocking severity, requires TFDA-equivalent label sourcing.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two randomized Phase 2 trials (CALGB 50904, CALGB 50901) plus multiple completed single-arm Phase 2 studies support ofatumumab activity in follicular lymphoma across frontline and relapsed settings, giving L2 evidence strength. However, activity in heavily pretreated/rituximab-refractory FL is modest (ORR 13% per PMID 22389254) and one Phase 3 combination trial (NCT01077518) was terminated early — this is not yet a clear-cut Go.

To proceed, the following is needed:

MOA/DrugBank mechanism-of-action data (DG002)
Regulatory label warnings and contraindications (DG001, Blocking — required before any safety pre-screen)
Clarification of ofatumumab’s actual marketing status, since this dataset shows 0 licenses despite known historical approvals
Head-to-head efficacy data vs. rituximab/obinutuzumab in FL to establish differentiated positioning
Route/dosing compatibility confirmation for the FL population (currently unassessed in this pack)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.